ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. will pay Germany’s BioNTech $30 million to develop cancer immunotherapies. The partners will identify tumor targets and their related functional T-cell receptors, which together can be engineered into therapies. Lilly will also take a stake worth $30 million in the biotech firm’s subsidiary Cell & Gene Therapies. In a separate cancer immunotherapy deal, Juno Therapeutics paid about $59 million in cash and $21 million in stock to acquire Stage Cell Therapeutics, a German biotech with expertise in cellular therapy manufacturing. Juno already owned a 5% stake in the firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter